Galera Therapeutics, Inc.
Galera Therapeutics, Inc. (GRTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
grtx · stock forecast · 9 analysts (3M) · FMP · updated May 31, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.09
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-16 | $0.09 | ↓ 3.77% |
1-day model range: $0.09–$0.09. Peak: $0.09 (-3.77%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · GRTX · Jun 15, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-29 | Citigroup | Maintains | Neutral→Neutral |
| 2023-08-16 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-08-10 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-07-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-03-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-02-21 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-02-16 | B of A Securities | Upgrade ↑ | Underperform→Buy |
| 2023-02-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-05-27 | B of A Securities | Downgrade ↓ | Neutral→Underperform |
| 2021-12-20 | Citigroup | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Galera Therapeutics, Inc. (GRTX) stock. Of the recent 22 rating actions, 4 were upgrades and 5 were downgrades. 9 analysts currently cover GRTX.
Analyst Recommendation Trends
GRTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$50M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$-0.08
EPS Next Year
$-0.78
↑ 851.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast GRTX EPS of $-0.08 for the current fiscal year, based on estimates from 1 analysts. The GRTX revenue forecast is $50M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GRTX stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GRTX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GRTX short-term stock prediction for tomorrow is $0.09 (-3.77%).
Galera Therapeutics, Inc. trades on OTC under the ticker GRTX. The GRTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
GRTX forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month GRTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.09.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.